TIUM Bio announced on the 3rd that it has recruited Vice President Kim Jeong-hoon as Head of the Development Division to strengthen the clinical and business development of its new drug pipeline.
New Vice President Kim Jeong-hoon completed his bachelor's and master's degrees at Seoul National University College of Pharmacy and earned an MBA from the University of Washington. After joining SK Chemicals in 1998, he served as Head of Pharma Planning and Director of the Research and Development Center. At SK Discovery, he was in charge of the Bio Strategy and Investment Division, responsible for establishing future growth strategies and investments for the group companies.
Vice President Kim said, “Based on 26 years of experience in business development (BD), planning, strategy, and research and development (R&D) in the pharmaceutical and bio industries at SK Chemicals and SK Discovery, I will lead TIUM Bio’s Clinical Development and Business Development teams to contribute to enhancing the company’s corporate value.”
Kim Hoon-taek, CEO of TIUM Bio, also said, “Clinical results for this year’s endometriosis and uterine fibroid treatment ‘Marigoldix (TU2670)’, oral immuno-oncology drug ‘TU2218’, and hemophilia treatment ‘TU7710’ are expected. At this important time when we need to generate business development outcomes accordingly, recruiting Vice President Kim Jeong-hoon makes us look forward to TIUM Bio’s 2024 even more.”
Meanwhile, TIUM Bio also announced executive promotions for 2024.
◆Promotions
△Vice Presidents ▶Head of Management Division Ko Hyun-sil ▶Head of Bio New Drug Division Song In-young
△Managing Director Jeon Jae-eun, Strategy Office
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
